Publications by authors named "David Olmos"

Claim this Profile
N
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, David Olmos

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?
Ignacio González-Ginel, Alfredo Rodriguez-Antolin, David Olmos, Elena Castro

Eur Urol Focus· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, Eleni Efstathiou, Gerhardt Attard, David Olmos

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.
Fred Saad, Alberto Briganti, Kunhi Parambath Haresh, Egils Vjaters, David Olmos

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.
Kim N Chi, Elena Castro, Gert Attard, Matthew R Smith, Shahneen Sandhu, David Olmos

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.
Johann S de Bono, Meng He, Zhen Shi, Malgorzata Nowicka, Sergio Bracarda, David Olmos

Eur Urol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff.
Elena Castro, David Lorente, David Olmos

Eur Urol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer.
Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunome profiling in prostate cancer: a guide for clinicians.
Luis San-Jose Manso, Arantzazu Alfranca, Ignacio Moreno-Pérez, María Ruiz-Vico, Clara Velasco, David Olmos

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer.
Antonio J Montero-Hidalgo, Juan M Jiménez-Vacas, Enrique Gómez-Gómez, Francisco Porcel-Pastrana, Prudencio Sáez-Martínez, David Olmos

Sci Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, Rafael Morales-Barrera, Francesco Grussu, David Olmos

Eur Urol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
Guilhem Roubaud, Gerhardt Attard, Martin Boegemann, David Olmos, Marco Trevisan

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomical factors of the maxillary tuberosity that influence molar distalization.
Diego Fernando López, David Acosta Olmos, Mónica Andrea Morales

Korean J Orthod· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Nuria Romero-Laorden, David Lorente, Guillermo de Velasco, Rebeca Lozano, Bernardo Herrera, David Olmos

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
Chiara Casadei, Emanuela Scarpi, Vincenza Conteduca, Giorgia Gurioli, Maria Concetta Cursano, David Olmos

Eur Urol Open Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in and/or in the PROfound Trial.
Joaquin Mateo, Johann S de Bono, Karim Fizazi, Fred Saad, Neal Shore, David Olmos

J Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, David Olmos

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, Elena Castro, Ronald de Wit, David Olmos

Eur Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Matthew R Smith, Shahneen Sandhu, Daniel J George, Kim Nguyen Chi, Fred Saad, David Olmos

J Manag Care Spec Pharm· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Rebeca Lozano, Elena Castro, Fernando Lopez-Campos, Heather Thorne, Miguel Ramirez-Backhaus, David Olmos

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Nobuaki Matsubara, Johann de Bono, Christopher Sweeney, Kim N Chi, David Olmos

Clin Genitourin Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.
Lorelei A Mucci, Jacob Vinson, Theresa Gold, Travis Gerke, Julie Filipenko, David Olmos

JCO Glob Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis